Clinical trials: Amyloid Beta-protein
Hydrocephalus, Normal Pressure, Biochemical Lesions Head Region
Role of Brain Specific Biomarkers in Hydrocephalus
Normal pressure hydrocephalus (NPH) is a neurodegenerative disease of unclear etiology characterized by a clinical trias named after the neurosurgeon Hakim.
- Conditions
- Hydrocephalus, Normal Pressure, Biochemical Lesions Head Region, Brain Damage
- Trial name
- NCT06083233
- Testing
- Lumbar puncture, External lumbar drainage, Ventriculo-peritoneal shunt placement
- Where
- Czechia
- Volunteers
- 32 people
- Sponsor
- University Hospital Hradec Kralove
Alzheimer Disease
Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects
Purpose: The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I AV151, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography…
- Trial name
- AV151 (NCT00605046)
- Testing
- SPECT scan
- Where
- 2 sites in United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Alzheimer's Disease
Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia
The purpose of this study is to determine the safety, tolerability and effect of JNJ-54861911 on level of amyloid-beta in Cerebrospinal Fluid (CSF) and plasma following 4 weeks of treatment in Japanese participants asymptomatic…
- Trial name
- NCT02360657
- Testing
- JNJ-54861911, 10 mg, JNJ-54861911, 50 mg
- Where
- 2 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Janssen Pharmaceutical K.K.
Dementia
Triglyceride-rich Lipoprotein and Development of Dementia
Because of the rapid aging of the global population, dementia has become a serious problem, and Alzheimer's disease (AD) is the most common cause of dementia.
- Trial name
- NCT02814422
- Where
- Taiwan
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Alzheimer Disease, Dementia
Exploratory Clinical Study and Validation of Blood Biomarkers for Alzheimer's Disease
This is a 24-month, monocentric, exploratory and observational clinical study aimed at developing and validating a blood-based diagnostic test for Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease, Dementia, Neurodegenerative Disorders, Cognitive Decline
- Trial name
- ADKIT (NCT07294586)
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Alzheimer Disease
Amyloid Beta-peptide 1-40 and Alzheimer's Disease
The combined measurement of Ab42 and tau protein (total and phosphorylated) in the spinal fluid has been shown to be promising in the diagnosis of Alzheimer's disease (AD), and has justified its inclusion new diagnostic criteria.
- Trial name
- ADAB40 (NCT02770482)
- Testing
- spinal fluid collection
- Where
- France
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- CHU de Reims
Alzheimer's Disease
Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age
The study determined the safety of CNP520 in healthy elderly over 3 months. Data relevant for Pharmacokinetic/Pharmacodynamic modeling were obtained in order to define the target dose in subsequent efficacy studies.
- Trial name
- NCT02576639
- Testing
- CNP520
- Where
- 11 sites in United States, Belgium and 3 more
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease, Cognitive Dysfunction, Cognitive Disorder
DIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community
The DIV-AD study aims to find out whether levels of Alzheimer's disease markers in blood differ among the main ethnical groups living in central Barcelona.
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Cognitive Disorder, Dementia, Neurodegenerative Disease
- Trial name
- DIV-AD (NCT07521722)
- Where
- Spain
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Alzheimer Disease
Truncated and Extended Forms of Amyloid Beta Peptides in Alzheimer's Disease: Genesis, Toxicity and Identification as Biological Markers
Beta amyloid immunoreactivity is probably due to a significant number of Ab catabolites corresponding to N-terminally truncated and Cterminally truncated or extended forms which display distinct propensity to aggregation.
- Trial name
- NCT01128725
- Testing
- Alzhamyd
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Down Syndrome, Amyloid Beta-protein
Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.
To determine the sensitivity of the visual assessment of BAY94-9172 PET images in detecting cerebral β-amyloid in individuals with Down Syndrome (DS) and specificity in individuals without DS.
- Trial name
- NCT00928304
- Testing
- Florbetaben (BAY94-9172)
- Where
- 2 sites in United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Lantheus Biosciences Ltd.
Cognitive Dysfunction, Alzheimer Disease
Association of Transcranial Alternating Current Stimulation with Digital Cognitive Training for Cognitive Remediation in Older Adults
BACKGROUND Cognitive decline in older adults, especially those who develop Mild Cognitive Impairment and Alzheimer's Disease, currently has limited options of pharmacological treatments, with modest efficacy.
- Conditions
- Cognitive Dysfunction, Alzheimer Disease, Mild Cognitive Impairment, Cognitive Decline
- Trial name
- NCT06733714
- Testing
- Transcranial Alternating Current Stimulation, Digital Cognitive Training
- Where
- Brazil
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do Rio de Janeiro
Alzheimer's Disease
A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease
The purpose of this study is to evaluate the changes in the cognitive, functional, behavioral and global domains based on the different applicable psychometric batteries and scales.
- Trial name
- AMBAR (NCT01561053)
- Testing
- Albumin 5%, Albumin 20%, Immunoglobulin
- Where
- 40 sites in United States, Spain
- Volunteers
- 347 people
- Sponsor
- Instituto Grifols, S.A.
Alzheimer Disease
Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I MNI-330, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT)…
- Trial name
- NCT00657813
- Testing
- MNI-330 as a brain SPECT tracer of Beta-Amyloid
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Alzheimer Disease
Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease
The aim of this study is to measure the effect of EGb 761® versus placebo on the ratio of the isoform of the protein precursor of beta amyloid platelets, in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00500500
- Testing
- EGb 761® (Tanakan®)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Ipsen
Alzheimer Disease
Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I AV94, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in…
- Trial name
- AV94 (NCT00605059)
- Testing
- [123I]AV94
- Where
- 2 sites in United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Stress, Ageing
The Relaxation vs. Retreat Study
The purpose of this research study is to examine whether a short term meditation intervention can improve health, mood, and biological markers of cellular stress and aging in novice and experienced meditators compared to controls.
- Conditions
- Stress, Ageing, Wellbeing
- Trial name
- R&R (NCT01857830)
- Testing
- Meditation Retreat, Active Comparator Relaxation Group
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Alzheimer Disease
A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of JNJ-54861911 in patients with prodromal Alzheimer's disease (pAD).
- Trial name
- NCT01978548
- Testing
- JNJ-54861911 10 mg, JNJ-54861911 50 mg
- Where
- 10 sites in Belgium, Netherlands and 2 more
- Volunteers
- 45 people
- Sponsor
- Janssen Research & Development, LLC
Disseminated Sclerosis
A Monocenter, Cross-sectional Study to Compare Different Type of Cognitive Impairment in Multiple Sclerosis Patients and Cerebrospinal Fluid Biomarkers (Beta Amyloid, Total Tau Protein and Tau-phosphorylated Protein).
In multiple sclerosis (MS) sub cortical cognitive impairments are frequently reported. Nevertheless, cortical cognitive troubles, with hippocampic memory troubles have been described.
- Trial name
- BioCogS (NCT00978536)
- Testing
- Cognitive impairment of multiple sclerosis
- Where
- France
- Volunteers
- 29 people
- Sponsor
- Nantes University Hospital
Amyloid-beta
Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction
The purpose of this study is to change the concentration of amyloid-beta in human cerebrospinal fluid (CSF) through modulation of the sleep-wake cycle.
- Trial name
- NCT02063217
- Testing
- Sodium Oxybate, Sleep deprivation
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Amyloid-beta
Sleep Quality and Amyloid-Beta Kinetics
The purpose of this study is to change the concentration of amyloid-beta in human cerebrospinal fluid (CSF) by modification of sleep efficiency.
- Trial name
- NCT03077620
- Testing
- Suvorexant
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine